Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices

References

• European Multiple Sclerosis Platform. MS Barometer (2011). Available from: www.emsp.org/attachments/article/160/MS_Barometer_2011.pdf [Last accessed 30 august 2012]
   Google Scholar
• Kobelt G, Kasteng F. Access to innovative treatments in rheumatoid arthritis in Europe: a report prepared for the European Federation of pharmaceutical industry associates (EFPIA) (2009). Available from: www.comparatorreports.se/Access%20to%20MS%20treatments%20-%20October%202009.pdf [Last accessed 18 October 2013]
   Google Scholar
• Towse A. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? Br J Clin Pharmacol 2010;70(3):360-6
   PubMed Web of Science ®Google Scholar
• Carlson J, Sullivan S, Garrison L, et al. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010;96(3):179-90
   PubMed Web of Science ®Google Scholar
• Garrison LPJr, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health 2013;16(50):703-19
   PubMed Web of Science ®Google Scholar
• Hammerman A, Feder-Bubis P, Greenberg D. Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders’ perceive interests. Value Health 2012;15(5):737-42
   PubMed Web of Science ®Google Scholar
• Vogler S, Zimmermann N, Habl C, et al. Discounts and rebates granted to public payers for medicines in European countries. South Med Rev 2012;5(1):38-46
   PubMedGoogle Scholar
• de Pouvourville G. Risk-sharing agreements for innovative drugs: a new solution to old problems? Eur J Health Econ 2006;7(3):155-7
   PubMedGoogle Scholar
• Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res 2013;13(6):735-41
   PubMed Web of Science ®Google Scholar
• Ridley DB. Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics 2005;23(7):651-8
   PubMed Web of Science ®Google Scholar
• SJEM. Act of 12 May 2011 on the refund of medicines, foodstuffs for particular nutritional uses and for medical devices [article in Polish] (2011). Available from: http://isap.sejm.gov.pl/DetailsServlet?id=WDU20111220696 [Last accessed 19 October 2013]
   Google Scholar
• Vienonen MA, Wlodarczyk WC. Health care reforms on the European scene: evolution, revolution or seesaw? World Health Stat Q 1993;46(3):166-9
   PubMedGoogle Scholar
• Sowada C. Health systems in the CEE accession states. In: Lutz W, Richter R, Wilson Chr, editors. The new generations of Europeans: demography and families in the enlarged European Union (population and sustainable development). Earthscan; London, UK: 2006. p. 288
   Google Scholar
• Kaló Z, Bodrogi J, Boncz I, et al. Capacity Building for HTA implementation in middle-income countries: the case of Hungary. Value in Health Regional Issues 2013;2(2):264-6
   PubMedGoogle Scholar
• Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. Value Health 2012;15(3):570-9
   PubMed Web of Science ®Google Scholar
• Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 2010;28(2):113-42
   PubMed Web of Science ®Google Scholar
• Adamski J, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 2010;10:153
   PubMed Web of Science ®Google Scholar
• Claxton K, Palmer S, Longworth L, et al. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. Health Technol Assess 2012;16(46):1-323
   PubMed Web of Science ®Google Scholar
• Green C, Bryant J, Takeda A, et al. Bortezomib for the treatment of multiple myeloma patients. Health Technol Assess 2009;13(Suppl 1):29-33
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (2009). Available from: http://publications.nice.org.uk/sunitinib-for-the-first-line-treatment-of-advanced-andor-metastatic-renal-cell-carcinoma-ta169 [Last accessed 18 October 2013]
   Google Scholar
• Pickin M, Cooper C, Chater T, et al. The multiple sclerosis risk sharing scheme monitoring study - early results and lessons for the future. BMC Neurology 2009;9:1
   PubMed Web of Science ®Google Scholar
• Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ 2010;340:c1672
   PubMedGoogle Scholar
• Møldrup C. No cure, no pay. BMJ 2005;330(7502):1262-4
   PubMed Web of Science ®Google Scholar
• Kolasa K, Wasiak R. Health technology assessment in Poland and Scotland: comparison of process and decisions. Int J Technol Assess Health Care 2012;28(1):70-6
   PubMed Web of Science ®Google Scholar
• Willis M, Persson U, Zoellner Y, Gradl B. Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden. Appl Health Econ Health Policy 2010;8(6):377-86
   PubMedGoogle Scholar
• Jarosławski S, Toumi M. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv Res 2011;11:259
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Ranibizumab and pegaptanib for treatment of age-related macular degeneration (2008; revised 2012). Available from: www.nice.org.uk/nicemedia/live/12057/41719/41719.pdf [Last accessed 18 October 2013]
   Google Scholar
• Mills J. NICE set to recommend Stelara for psoriasis. SCRIP Intelligence (17 August 2009). Available from: www.scripintelligence.com/policyregulation/NICE-set-to-recommend-Stelara-for-psoriasis-173593 [Last accessed 19 October 2013]
   Google Scholar
• Health Consumer Powerhouse, The Empowerment of the European Patient 2009 – options and implications. Available from: www.healthpowerhouse.com/files/EPEI-2009/european-patient-empowerment-2009-report.pdf [Last accessed 19 October 2013]
   Google Scholar
• Project Group on facilitating supply in small markets. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/smallmarkets_positionpaper_en.pdf [Last accessed 10 December 2013]
   Google Scholar
• Lu C, Williams K, Day R, et al. Access to high cost drugs in Australia. BMJ 2004;329(7463):415-16
   PubMed Web of Science ®Google Scholar
• Rutten F, Uyl-de Groot C, Vulto A. Innovative payment systems for medicines in Europe. EJHP Pract 2009;15:60-2
   Google Scholar
• Towse A, Garrison LPJr. Can’t get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics 2010;28(2):93-102
   PubMed Web of Science ®Google Scholar
• Sparrowhawk K. Commentary: NICE shares risk with the drug industry. SCRIP Intelligence (5 September 2007). Available from: www.scripintelligence.com/home/news/Commentary-NICE-National-Institute-for-health-and-Clinical-Excellence-shares-risk-with-the-drug-industry---by-Keiron-Sparrowhawk-of-Pricespective-36430 [Last accessed 19 October 2013]
   Google Scholar
• Wagstaff A. Health rationing in Europe: can cancer get a fair hearing? Cancer World (2009). Available from: www.cancerworld.org/Articles/Issues/30/May-June-2009/Drug-Watch/33/Health-rationing-in-Europe-can-cancer-get-a-fair-hearing-.html [Last accessed 19 October 2013]
   Google Scholar
• National Institute for Health and Clinical Excellence. Rituximab for aggressive non-Hodgkin’s lymphoma (2003). Available from: www.nice.org.uk/nicemedia/live/11506/32679/32679.pdf [Last accessed 19 October 2013]
   Google Scholar
• National Institute for Health and Clinical Excellence. National Collaborating Centre for Women’s and Children’s Health. Diagnosis and management of type 1 diabetes in children and young people (2004). Available from: www.nice.org.uk/nicemedia/pdf/CG015childrenfullguideline.pdf [Last accessed 19 October 2013]
   Google Scholar
• Thomson D. British oncology pharmacy association: position statement on “risk sharing” schemes in oncology (March 2008). Available from: www.bopawebsite.org/contentimages/publications/Position_Statement_on_Risk_Sharing_ProgrammesFINAL__2_.pdf [Last accessed 19 October 2013]
   Google Scholar
• Gajraj E, Chung H, Boysen M, et al. 2009;Lenalidomide for the treatment of relapsed multiple myeloma. Lancet 2009;10(7):647-8
   Web of Science ®Google Scholar
• Shearer L. CIGNA and Merck sign performance-based contract (23 April 2009). Available from: http://newsroom.cigna.com/article_display.cfm?article_id=1043 [Last accessed 19 October 2013]
   Google Scholar
• Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing remitting multiple sclerosis. J Manag Care Pharm 2009;15(7):543-55
   PubMed Web of Science ®Google Scholar
• Lilford RJ. MS risk sharing scheme. Response from chair of scientific advisory committee. BMJ 2010;341:c3590
   Google Scholar
• Richards RG. MS risk sharing scheme. Some clarification needed. BMJ 2010;341:c3589
   Google Scholar
• Messori A. MS risk sharing scheme. Outcome based schemes are more common than you think. BMJ 2010;341:c3588
   Google Scholar
• Scolding N. The multiple sclerosis risk sharing scheme. BMJ 2010;340:c2882
   Google Scholar
• McCabe C, Chilcott J, Claxton K, et al. Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ 2010;340:c1786
   PubMedGoogle Scholar
• Boggild M, Palace J, Barton P, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ 2009;339:b4677
   PubMed Web of Science ®Google Scholar
• Sudlow CL, Counsell CE. Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003;326(7385):388-92
   PubMed Web of Science ®Google Scholar
• Chalkidou K. “Only in research”: a polite “no” or a valuable policy option? (2006). Available from: www.healthlinks-events.co.uk/nice2006/h11a_thu_1145_chalkidou.pdf [Last accessed 19 October 2013]
   Google Scholar
• Gallo PF, Deambrosis P. Pharmaceutical risk-sharing and conditional reimbursement in Italy (2008). Available from: www.ceestahc.org/pliki/symp2008/gallo.pdf [Last accessed 19 October 2013]
   Google Scholar
• Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur J Health Econ 2010;11(2):195-203
   PubMed Web of Science ®Google Scholar